ESMO ban 728x90

SECOND DAY

Thursday September 28th

DNA DAMAGE RESPONSE

8.30-10.00 Session I:
François-Xavier DANLOS/Sophie POSTEL-VINAY

  8.30-9.00: Exploiting self-inflicted DNA breaks to evade growth limits imposed by genotoxic stress
Dr Claus Sørensen, University of Copenhagen, D


  9.00-9.30: Chromosomal instability-induced inflammation: a catch 22 for cancer cells
Dr Floris Foijer, University of Groningen, NL


  9.30-10.00: A new role of altered R-loop homeostasis in radiation-induced tumor immunogenicity
Pr Sandra Demaria, Weill Cornell Medicine, USA


  10.00-10.30 Coffee break

MYELOID CELLS

  10.30-12.30 Session II:
Paul BERGERON/Julie CONSTANZO

  10.30-11.00: Myeloid cells in cancer
Dr Mikael Pittet, University of Geneva, SW


  11.00-11.30: Neutrophils in lung cancer: modulators of tumor growth and therapy response
Dr Etienne Meylan, Université Libre de Bruxelles, B


  11.30-12.00: Local and abscopal responses of small-cell lung cancer to radiation therapy
Pr Julien Sage, Stanford University, USA


  12.00-12.30: Enhancing phagocytosis to magnify radiotherapy-induced in situ tumor vaccination
Dr Rodney Cheng-En Hsieh, Chang Gung Memorial Hospital, Taiwan


  12.30-14.00 Lunch break and exhibition

 RT DOSE AND MODALITIES

14.00-16.00: Session III:
Pierre-Antoine LAURENT/Céline MIRJOLET

  14.00-14.30: Spatially fractionated FLASH radiotherapy modulates the antitumor immune response
Dr Cristian Fernandez-Palomo, University of Bern, SW


  14.30-15.00: Radiotherapy with carbon ions plus CTLA4 blockade elicits therapeutic immune responses in a murine tumor model
Dr Stefan Eichmuller, DKFZ Heidelberg, G


  15.00-15.30: Revisiting the radiobiology of targeted alpha therapy
Dr Jean-Pierre Pouget, Institut de Recherche en Cancérologie de Montpellier, FR


  15.30-16.00: Radiotherapy in the context of multimodality treatment for oligometastatic disease
Pr Matthias Guckenberger, University of Zurich, SW


  16.00-16.30 coffee break

IMMUNOSUPPRESSION

  16.30-18.00 Session IV:
Michele MONDINI/Inigo MARTINEZ-ZUBIAURRE

  16.30-17.00: IL-1, CAFs and rectal cancer
Dr Florian Greten, Frankfurt University, G


  17.00-17.30: Innovative approaches to trigger radiation induced immunological cell death and overcome checkpoint resistance
Pr Jim Welsh, MD Anderson Cancer Center, USA


Keynote Presentation

  17.30-18.15: Barriers that hinder immune response in the irradiated tumor: an insurmountable challenge or opportunity for innovation?
Pr Ralph Weichselbaum, University of Chicago, USA

 
Cookie Policy

This website uses cookies that are necessary to its functioning and required to achieve the purposes illustrated in the privacy policy. By accepting this OR scrolling this page OR continuing to browse, you agree to our privacy policy.